Magazine Article | October 3, 2022

Outsourced Proportion Of Phase 2/3 Spend

Source: Life Science Leader

By Industry Standard Research

ISR recently ran a survey to assess dynamics in the Phase 2/3 clinical development space. Survey respondents reported that, on average, two-thirds of their company’s spend on Phase 2/3 studies over the past year was outsourced. According to survey participants, large sponsors outsourced roughly half of their Phase 2/3 spend (55%), while midsize and small sponsors outsourced 73% and 80% of their spend, respectively.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader